Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Madrigal Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (88)	4/4/2019 12:12:54 PM
From: DewDiligence_on_SI	Respond to of 138

I don't know the reason for GLP-1 and vitamin-E exclusions. Are there any DDI issues?

To: Miljenko Zuanic who wrote (88)	4/4/2019 7:43:56 PM
From: keokalani'nui	Read Replies (2) \| Respond to of 138

This review from 2018 suggests you are correct. ncbi.nlm.nih.gov >>No pharmacological therapies are approved for the treatment of NAFLD and lifestyle changes focusing on caloric restriction and weight loss constitute the general treatment recommendations. Recent trials investigating glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists (GLP-1RAs) for the treatment of NAFLD have shown promising results. Furthermore, GLP-1R/glucagon receptor dual agonists are being investigated for the treatment of NAFLD ( 12). In addition to its effects on glucose metabolism, glucagon is suggested to induce body weight loss, by increasing satiety and enhancing hepatic lipid oxidation and whole-body energy expenditure ( 13). This review provides (1) insights into the pathogenesis of NAFLD including the potential involvement of GLP-1 and glucagon, (2) a critical appraisal of the applicability of GLP-1RAs in NAFLD treatment, and (3) a review of the evidence for GLP-1/glucagon receptor co-agonism as a novel approach in the treatment of NAFLD.<<